Related Experiment Video
Updated: Jun 13, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
[Recurrent aphthosis: safety of low dose thalidomide]
1Service de médecine interne, CHU Jean-Minjoz, 1, boulevard Fleming, 25000 Besançon, France. hgil@chu-besancon.fr
Purpose:
Thalidomide is an effective treatment for recurrent aphthosis but its effectiveness at low dose has been rarely assessed.
Methods:
Single-centre non-randomized retrospective open study.
Results:
Forty-seven patients were treated with thalidomide for recurrent aphthosis (41 patients) or Behçet disease (six patients). Remission was obtained with a dose of 25 mg daily. Discontinuation of treatment for side effects was not observed in this case series.
Conclusion:
Low dose thalidomide below 50 mg daily is an effective and well tolerated treatment of aphthosis.
Related Concept Videos
Teratogenicity
Drug Toxicity: Risk factors
Drug Dosing: Infants and Children
Acne Infection
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drug Regulation
